Nanoparticles capable of managing hypoglycemia and preventing myocardial ischemia‐reperfusion injury.

Diabetes, and its complications, is a major threat to human health. In this research, we successfully synthesized a new type of glucose‐responsive poly(3‐acrylamidophenylboronic acid‐co‐pterostilbene) (p(AAPBA‐co‐PTE) nanoparticle. The nanoparticles are round in shape with a size between 150 and 200 nm. Insulin‐loaded p(AAPBA‐co‐PTE) nanoparticles can self‐adjust according to the changes in glucose concentration in vitro to achieve effective and sustained levels of insulin. P(AAPBA‐co‐PTE) nanoparticles have good stability, and the drug loading of insulin‐loaded p(AAPBA‐co‐PTE) nanoparticles is up to 16.7%, the encapsulation efficiency is up to 82.4% and the release rate of pterostilbene in vitro is up to 81%. The p(AAPBA‐co‐PTE) nanoparticles have low toxicity toward cells, and can effectively reduce blood sugar within 24 h. After 14 days of treatment, an animal model of myocardial ischemia‐reperfusion injury (MI/RI) was established. After treatment with the insulin‐loaded p(AAPBA‐co‐PTE) nanoparticles, the rat heart function was significantly improved, and the levels of inflammatory factors were significantly reduced. P(AAPBA‐co‐PTE) nanoparticles were therefore successfully synthesized, and had good performance. P(AAPBA‐co‐PTE) nanoparticles appear to have the effect of reducing blood sugar and preventing MI/RI, and may be valuable for the development of treatments for MI/RI. [ABSTRACT FROM AUTHOR]